The Company was incorporated.
The Company completed our Series A financing and raised a total of USD10 million in June.
The Company completed a single-center feasibility clinical trial on ten patients in China for TaurusOne® in August.
The Company started the multi-center confirmatory clinical trial in China for TaurusOne® in September.
Achieva Medical became our subsidiary through a share swap agreement in March.
The Company completed our Series B financing and raised approximately USD29 million in February.
The Company obtained the NMPA Registration Certificate for our Yibida® Guiding Catheter in May.
The Company completed our Series C financing and raised a total of USD25 million in September.
The Company launched sales of our second-generation Presgo® Detachable Coil in October.
The Company completed our Series C-1 financing and raised a total of USD45 million in December.
The Company initiated the clinical trial for TaurusElite®, our second-generation TAVR device, in December.
In May, the Company was listed on The Stock Exchange of Hong Kong Limited under the stock code of 9996.
In August, the Company obtained National Food and Drug Administration approval for SacSpeed® Balloon Dilatation Catheter.
In September, the Company obtained the Contract Manufacturing License (委託生產許可) to manufacture the Jasper® Detachable Coil under the Jiangsu Pilot Marketing Authorization Holder (MAH) System (江蘇醫療器械註冊人制度試點).
In September, the Company received a confirmation letter from the National Medical Products Administration of the People’s Republic of China (國家藥品監督管理局) that confirms its acceptance of the registration application for TaurusOne®